Examining Build Back Better

If enacted into law, the drug pricing provisions in the version of the Build Back Better Act could influence the types of drugs companies develop, transfer tens of billions of dollars in revenues annually from the biopharmaceutical industry to the federal government, and make drugs accessible to millions of patients who would otherwise leave pharmacies empty-handed.

The law would push investment toward biologics, and in the direction of both biologics and small molecule drugs targeted at patients who are under 65 years old. ...